Bicara Therapeutics Inc. (BCAX)Healthcare | Biotechnology | Boston, United States | NasdaqGM
28.15 USD
-0.76
(-2.629%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 28.15 |
Hot Take ↕ | July 11, 2026, 3:15 a.m. EDT
The recent price surge to nearly $30 is a classic biotech 'event-driven' spike, likely fueled by the Q1 earnings call and the all-time high headline, but the underlying fundamentals tell a starkly different story. The company is burning cash aggressively with negative free cash flow and negative operating cash flow, while insiders including the President and CFO have sold hundreds of thousands of dollars worth of stock recently—a clear signal that management sees limited upside at these levels. The balance sheet is technically clean due to minimal debt, but the business is not generating revenue or profits. The options market confirms this skepticism; traders are buying cheap put insurance for the coming months rather than betting on a breakout. While the stock has rallied off its lows, the lack of sustainable earnings growth and the heavy insider selling suggest this rally is fragile. This is a speculative play on a binary event, not a sound investment vehicle. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.082269 |
| AutoETS | 0.082299 |
| AutoTheta | 0.082330 |
| MSTL | 0.084731 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 8.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.007 |
| Excess Kurtosis | 0.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.28 |
| Market Cap | 1,849,563,776 |
| Forward P/E | -7.75 |
| Website | https://www.bicara.com |
As of July 11, 2026, 3:15 a.m. EDT: Speculators are positioning heavily for downside protection via deep out-of-the-money puts expiring in August and January 2027, creating a significant 'insurance' wall against further declines. Conversely, call activity is sparse and concentrated in near-term expirations, indicating a lack of aggressive bullish conviction despite the recent price rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.8398821 |
| Address1 | 116 Huntington Avenue |
| Address2 | Suite 703 |
| All Time High | 30.99 |
| All Time Low | 7.8 |
| Ask | 35.87 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 1,347,150 |
| Average Daily Volume3 Month | 694,968 |
| Average Volume | 694,968 |
| Average Volume10Days | 1,347,150 |
| Bid | 20.22 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 7.841 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 28.15 |
| Current Ratio | 13.851 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 28.535 |
| Day Low | 27.5662 |
| Debt To Equity | 0.28 |
| Display Name | Bicara Therapeutics |
| Earnings Call Timestamp End | 1,778,502,600 |
| Earnings Call Timestamp Start | 1,778,502,600 |
| Earnings Timestamp | 1,778,502,600 |
| Earnings Timestamp End | 1,786,451,400 |
| Earnings Timestamp Start | 1,786,451,400 |
| Ebitda | -173,928,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.539 |
| Enterprise Value | 1,311,251,840 |
| Eps Current Year | -3.47769 |
| Eps Forward | -3.6325 |
| Eps Trailing Twelve Months | -2.77 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 23.2614 |
| Fifty Day Average Change | 4.8885994 |
| Fifty Day Average Change Percent | 0.21015929 |
| Fifty Two Week Change Percent | 183.98822 |
| Fifty Two Week High | 30.99 |
| Fifty Two Week High Change | -2.8400002 |
| Fifty Two Week High Change Percent | -0.09164247 |
| Fifty Two Week Low | 9.57 |
| Fifty Two Week Low Change | 18.58 |
| Fifty Two Week Low Change Percent | 1.9414839 |
| Fifty Two Week Range | 9.57 - 30.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,726,234,200,000 |
| Float Shares | 36,679,183 |
| Forward Eps | -3.6325 |
| Forward P E | -7.749484 |
| Free Cashflow | -68,385,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 103 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.101780005 |
| Held Percent Institutions | 1.0436699 |
| Implied Shares Outstanding | 65,703,866 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-09-13 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. |
| Long Name | Bicara Therapeutics Inc. |
| Market | us_market |
| Market Cap | 1,849,563,776 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_674698236 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -157,315,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,897,527,650 |
| Number Of Analyst Opinions | 13 |
| Open | 28.535 |
| Operating Cashflow | -116,236,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 468 4219 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 28.15 |
| Post Market Time | 1,783,981,120 |
| Previous Close | 28.91 |
| Price Eps Current Year | -8.094454 |
| Price Hint | 2 |
| Price To Book | 3.5901031 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.72 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.76 |
| Regular Market Change Percent | -2.62885 |
| Regular Market Day High | 28.535 |
| Regular Market Day Low | 27.5662 |
| Regular Market Day Range | 27.5662 - 28.535 |
| Regular Market Open | 28.535 |
| Regular Market Previous Close | 28.91 |
| Regular Market Price | 28.15 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 416,540 |
| Return On Assets | -0.21089001 |
| Return On Equity | -0.32339 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 65,703,866 |
| Shares Percent Shares Out | 0.1541 |
| Shares Short | 10,121,649 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 10,083,302 |
| Short Name | Bicara Therapeutics Inc. |
| Short Percent Of Float | 0.2152 |
| Short Ratio | 10.8 |
| Source Interval | 15 |
| State | MA |
| Symbol | BCAX |
| Target High Price | 46.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 31.46154 |
| Target Median Price | 31.0 |
| Total Cash | 539,753,024 |
| Total Cash Per Share | 8.215 |
| Total Debt | 1,441,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.77 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.027775 |
| Two Hundred Day Average Change | 9.122225 |
| Two Hundred Day Average Change Percent | 0.47941628 |
| Type Disp | Equity |
| Volume | 416,540 |
| Website | https://www.bicara.com |
| Zip | 2,116 |